16:40 uur 17-05-2018

BioClin Therapeutica, Inc. kondigt de presentatie aan van B-701 tijdens de jaarlijkse vergadering van de American Society of Clinical Oncology (ASCO) in 2018

SAN LEANDRO, Calif.–(BUSINESS WIRE)– BioClin Therapeutics, Inc., een klinisch bedrijf dat geneesmiddelen ontwikkelt, kondigt vandaag aan dat gegevens zullen worden gepresenteerd uit de lopende Fase 1b/2 studie van B-701, een eerste klasse anti-fibroblast groeifactor receptor 3 (FGFR3) monoklonaal antilichaam, plus docetaxel voor metastatische blaaskanker op een affichesessie tijdens de vergadering van de American Society for Clinical Oncology (ASCO) die op 1 tot en met 5 juni 2018 in Chicago, IL wordt georganiseerd.

De details van de posterpresentatie zijn als volgt:

[Abstract 4534]
FIERCE-21: Fase 1b/2 studie van Docetaxel + B-701, een selectieve remmer van FGFR3, in Relapsed or Refractory (R/R) Metastatic Urothelial Carcinoma (mUCC)

Joaquim Bellmunt, M.D., Ph.D., Dana-Farber Cancer Institute
Sessie: Urogenitale (niet-prostate) Kanker
Postersessie Datum/Tijd: Zaterdag, 3 juni 2018, 8:00 – 11:30 uur, CDT, Hal A.

Over BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is een biotechnologisch bedrijf in de klinische fase in privé-bezit dat biologische geneesmiddelen ontwikkelt om medische aandoeningen te bestrijden in gebieden met grote behoefte daaraan. Het bedrijf richt zich op FGFR3 (Fibroblast Groei Factor Receptor 3), een driver mutatie in metastatische blaaskanker en mogelijk andere kankersoorten. Het hoofdprogramma van het bedrijf, B-701, is het enige gerichte biologisch gerichte FGFR3 in klinische ontwikkeling. BioClin heeft lopende klinische studies in metastatische blaaskanker met inbegrip van B-701 monotherapie en B-701 in combinatie met standaard – van – zorg chemotherapie, net als pembrolizumab, een immuuncontroleposter.

BioClin Therapeutics, Inc. Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN LEANDRO, Calif.–(BUSINESS WIRE)– BioClin Therapeutics, Inc., a clinical stage drug development company announced today that data will be presented from its ongoing Phase 1b/2 study of B-701, a first-in-class anti-fibroblast growth factor receptor 3 (FGFR3) monoclonal antibody, plus docetaxel for metastatic bladder cancer at a poster session at the 2018 American Society for Clinical Oncology (ASCO) meeting being held June 1-5, 2018 in Chicago, IL.

The details of the poster presentation are as follows:

[Abstract 4534]
FIERCE-21: Phase 1b/2 study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory (R/R) Metastatic Urothelial Carcinoma (mUCC).

Joaquim Bellmunt, M.D., Ph.D., Dana-Farber Cancer Institute
Session: Genitourinary (Nonprostate) Cancer
Poster Session Date/Time: Saturday, June 3, 2018, 8:00 – 11:30 a.m., CDT, Hall A

About BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.

For more information, please visit BioClin’s website: www.bioclintherapeutics.com

Forward-Looking Statement:

This press release contains forward-looking statements about the business and prospects of BioClin Therapeutics, Inc., which involve risks and uncertainties, including, without limitation, statements about the timing and plans to conduct clinical trials of B-701 in mUC. These risks and uncertainties include, among others: timing of enrollment in and results of the clinical trials; safety of B-701 alone or in combination with other therapies; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning B-701. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. BioClin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Contacts

BioClin Therapeutics, Inc.
Stephen Lau
Chief Executive Officer
info@bioclintherapeutics.com

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr